Deutsche Bank
BCAX

Deutsche Bank’s Bicara Therapeutics BCAX Stock Holding History

Deutsche Bank’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Buy
131,656
+3,030
+2% +$52.2K ﹤0.01% 1637
2025
Q4 		$2.16M Buy
128,626
+1,171
+0.9% +$20K ﹤0.01% 1752
2025
Q3 		$2.01M Buy
127,455
+3,370
+3% +$37.7K ﹤0.01% 1771
2025
Q2 		$1.15M Buy
124,085
+12,702
+11% +$151K ﹤0.01% 2008
2025
Q1 		$1.45M Sell
111,383
-1,093
-1% -$14.5K ﹤0.01% 1956
2024
Q4 		$1.96M Buy
+112,476
New +$2.34M ﹤0.01% 1866

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Deutsche Bank's BCAX Position: Q1 2026 in Review

Deutsche Bank increased its Bicara Therapeutics (BCAX) stake by 2.4% in Q1 2026, buying an estimated $52.2K and bringing the position to 131,656 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Deutsche Bank first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Deutsche Bank held 131,656 shares of Bicara Therapeutics worth $2.62M as of Q1 2026.
  • Deutsche Bank bought 3,030 Bicara Therapeutics shares in Q1 2026, an estimated $52.2K.
  • Bicara Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1637 holding.
  • Deutsche Bank first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.